Risk-adjusted therapy for pediatric non-T cell ALL improves outcomes for standard risk patients: results of JACLS ALL-02 - Hasegawa, D; Imamura, T; Yumura-Yagi, K; Japan Association of Childhood Leukemia Study Group (JACLS) (Blood Cancer J, 2020)